Preclinical assessment of drug-induced proarrhythmias: Role of the arterially perfused rabbit left ventricular wedge preparation

Pharmacology and Therapeutics

Volumn 119, Issue 2, 2008, Pages 141-151

  Wang, Dongqi ^a   Patel, Chinmay ^b   Cui, Changcong ^a   Yan, Gan Xin ^a,b,c  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b Main Line Health Heart Center   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Drug safety; Preclinical model; Proarrhythmias; Rabbit ventricular wedge preparation; Torsade de pointes

Indexed keywords

AMIODARONE; AZITHROMYCIN; BUCHANG WENXIN KELI; CAPTOPRIL; CHINESE DRUG; CISAPRIDE; CLARITHROMYCIN; CLOZAPINE; DESIPRAMINE; DIMETHYL SULFOXIDE; DOFETILIDE; ERYTHROMYCIN; FEXOFENADINE; FLUOXETINE; GREPAFLOXACIN; MOXIFLOXACIN; PENTOBARBITAL; POTASSIUM CHANNEL HERG; RANOLAZINE; SPARFLOXACIN; TELITHROMYCIN; TERFENADINE; THIORIDAZINE; UNCLASSIFIED DRUG; VERAPAMIL;

CLINICAL ASSESSMENT; DRUG INDUCED DISEASE; DRUG SAFETY; ELECTROCARDIOGRAM; ELECTROPHYSIOLOGY; ENDOCARDIUM; EPICARDIUM; GENE; HEART ARRHYTHMIA; HEART DEPOLARIZATION; HEART LEFT VENTRICLE; HEART MUSCLE POTENTIAL; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HUMAN; MODEL; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RABBIT; REVIEW; RISK; SCORING SYSTEM; T WAVE; TECHNIQUE; TORSADE DES POINTES; VALIDATION PROCESS; WEDGE TECHNIQUE;

ANIMALS; ARRHYTHMIAS, CARDIAC; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FEMALE; HEART VENTRICLES; HUMANS; PHARMACEUTICAL PREPARATIONS; RABBITS; TORSADES DE POINTES; TOXICITY TESTS;

EID: 48149093518     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2008.02.009     Document Type: Review

References (52)

1. Ando K., Hombo T., Kanno A., Ikeda H., Imaizumi M., Shimizu N., et al. QT PRODACT: In vivo QT assay with a conscious monkey for assessment of the potential for drug-induced QT interval prolongation. J Pharmacol Sci 99 (2005) 487-500
2. Antimisiaris M., Sarma J.S., Schoenbaum M.P., Sharma P.P., Venkataraman K., and Singh B.N. Effects of amiodarone on the circadian rhythm and power spectral changes of heart rate and QT interval: Significance for the control of sudden cardiac death. Am Heart J 128 (1994) 884-891
3. Antzelevitch C. Arrhythmogenic mechanisms of QT prolonging drugs: Is QT prolongation really the problem?. J Electrocardiol 37 Suppl (2004) 15-24
4. Antzelevitch C. Heterogeneity and cardiac arrhythmias: An overview. Heart Rhythm 4 (2007) 964-972
5. Antzelevitch C., and Shimizu W. Cellular mechanisms underlying the long QT syndrome. Curr Opin Cardiol 17 (2002) 43-51
6. Belardinelli L., Antzelevitch C., and Vos M.A. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 24 (2003) 619-625
7. Belardinelli L., Shryock J.C., Wu L., and Song Y. Use of preclinical assays to predict risk of drug-induced torsades de pointes. Heart Rhythm 2 (2005) S16-S22
8. Bjerregaard P., and Gussak I. Short QT syndrome: mechanisms, diagnosis and treatment. Nat Clin Pract Cardiovasc Med 2 (2005) 84-87
9. CAST Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) investigators. N Engl J Med 321 (1989) 406-412
10. Chen X., Cordes J.S., Bradley J.A., Sun Z., and Zhou J. Use of arterially perfused rabbit ventricular wedge in predicting arrhythmogenic potentials of drugs. J Pharmacol Toxicol Methods 54 (2006) 261-272
11. Di Diego J.M., Belardinelli L., and Antzelevitch C. Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation 108 (2003) 1027-1033
12. Extramiana F., and Antzelevitch C. Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome. Circulation 110 (2004) 3661-3666
13. Fossa A.A., DePasquale M.J., Raunig D.L., Avery M.J., and Leishman D.J. The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment. J Pharmacol Exp Ther 302 (2002) 828-833
14. Guo D., Zhou J., Zhao X., Gupta P., Kowey P.R., Martin J., et al. L-type calcium current recovery versus ventricular repolarization: Preserved membrane-stabilizing mechanism for different QT intervals across species. Heart Rhythm 5 (2008) 271-279
15. Gussak I., and Bjerregaard P. Short QT syndrome-5 years of progress. J Electrocardiol 38 (2005) 375-377
16. Gussak I., Brugada P., Brugada J., Antzelevitch C., Osbakken M., and Bjerregaard P. ECG phenomenon of idiopathic and paradoxical short QT intervals. Card Electrophysiol Rev 6 (2002) 49-53
17. Haverkamp W., Breithardt G., Camm A.J., Janse M.J., Rosen M.R., Antzelevitch C., et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 47 (2000) 219-233
18. Hondeghem L.M., Dujardin K., and De Clerck F. Phase 2 prolongation, in the absence of instability and triangulation, antagonizes class III proarrhythmia. Cardiovasc Res 50 (2001) 345-353
19. Joshi A., Dimino T., Vohra Y., Cui C., and Yan G.X. Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: The role of experimental models. J Electrocardiol 37 Suppl (2004) 7-14
20. Kowey P., Yan G., and Crijns H. Antiarrhythmic drugs. In: Fuster V., Poole-Wilson P., O'Rourke R., and Walsh R. (Eds). Hurst's the heart (2007), The McGraw-Hill Companies, Inc
21. Lankipalli R.S., Zhu T., Guo D., and Yan G.X. Mechanisms underlying arrhythmogenesis in long QT syndrome. J Electrocardiol 38 (2005) 69-73
22. Lawrence C.L., Pollard C.E., Hammond T.G., and Valentin J.P. Nonclinical proarrhythmia models: Predicting Torsades de Pointes. J Pharmacol Toxicol Methods 52 (2005) 46-59
23. Liu T., Brown B.S., Wu Y., Antzelevitch C., Kowey P.R., and Yan G.X. Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm 3 (2006) 948-956
24. Liu T., Choi B.R., Drici M.D., and Salama G. Sex modulates the arrhythmogenic substrate in prepubertal rabbit hearts with Long QT 2. J Cardiovasc Electrophysiol 16 (2005) 516-524
25. Lu H.R., Vlaminckx E., Van de W.A., Rohrbacher J., Hermans A., and Gallacher D.J. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation. Eur J Pharmacol 577 (2007) 222-232
26. Martin R.L., McDermott J.S., Salmen H.J., Palmatier J., Cox B.F., and Gintant G.A. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: Influence of multi-channel block. J Cardiovasc Pharmacol 43 (2004) 369-379
27. Mattioni T.A., Zheutlin T.A., Sarmiento J.J., Parker M., Lesch M., and Kehoe R.F. Amiodarone in patients with previous drug-mediated torsades de pointes: Long-term safety and efficacy. Ann Intern Med (1989) 574-580
28. Milberg P., Ramtin S., Monnig G., Osada N., Wasmer K., Breithardt G., et al. Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block. J Cardiovasc Pharmacol 44 (2004) 278-286
29. Morganroth J., DiMarco J.P., Anzueto A., Niederman M.S., and Choudhri S. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest 128 (2005) 3398-3406
30. Patel C., and Antzelevitch C. Cellular Basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome. Heart Rhythm 5 (2008) 585-590
31. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc Res 58 (2003) 32-45
32. Roden D.M. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol 21 (1998) 1029-1034
33. Roden D.M. Drug-induced prolongation of the QT interval. N Engl J Med 350 (2004) 1013-1022
34. Salata J.J., Jurkiewicz N.K., Jow B., Folander K., Guinosso P.J., Raynor B., et al. Ik of rabbit ventricle is composed of two currents: Evidence for Iks. Am J Physiol 271 Heart Circ. Physiol. 40 (1996) H2477-H2489
35. Shimizu W., Ohe T., Kurita T., Kawade M., Arakaki Y., Aihara N., et al. Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. J Am Coll Cardiol 26 (1995) 1299-1309
36. Sicouri S., and Antzelevitch C. A subpopulation of cells with unique electrophysiological properties in the deep subepicardium of the canine ventricle. The M cell. Circ Res 68 (1991) 1729-1741
37. Terrar D.A., Wilson C.M., Graham S.G., Bryant S.M., and Heath B.M. Comparison of guinea-pig ventricular myocytes and dog Purkinje fibres for in vitro assessment of drug-induced delayed repolarization. J Pharmacol Toxicol Methods 56 (2007) 171-185
38. Thomsen M.B., Matz J., Volders P.G., and Vos M.A. Assessing the proarrhythmic potential of drugs: Current status of models and surrogate parameters of torsades de pointes arrhythmias. Pharmacol Ther 112 (2006) 150-170
39. Tomaselli G.F., and Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res 42 (1999) 270-283
40. van Opstal J.M., Leunissen J.D., Wellens H.J., and Vos M.A. Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of Torsade de Pointes arrhythmias. Eur J Pharmacol 412 (2001) 67-76
41. van Opstal J.M., Schoenmakers M., Verduyn S.C., De Groot S.H., Leunissen J.D., Der Hulst F.F., et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation 104 (2001) 2722-2727
42. Vos M.A. Do we understand the electrophysiologic mechanisms responsible for drug-induced cardiac arrhythmias?. J Cardiovasc Pharmacol 40 (2002) 647-650
43. Vos M.A., van Opstal J.M., Leunissen J.D., and Verduyn S.C. Electrophysiologic parameters and predisposing factors in the generation of drug-induced Torsade de Pointes arrhythmias. Pharmacol Ther 92 (2001) 109-122
44. Xu X., Rials S.J., Wu Y., Salata J.J., Liu T., Bharucha D., et al. Left ventricular hypertrophy decreases slowly, but not rapidly activating delayed rectifier K+ currents of epicardial and endocardial myocytes in rabbits. Circulation 103 (2001) 1585-1590
45. Xu X., Salata J.J., Wang J., Wu Y., Yan G.X., Liu T., et al. Increasing I(Ks) corrects abnormal repolarization in rabbit models of acquired LQT2 and ventricular hypertrophy. Am J Physiol Heart Circ Physiol 283 (2002) H664-H670
46. Yan G.X., and Antzelevitch C. Cellular basis for the electrocardiographic J wave. Circulation 93 (1996) 372-379
47. Yan G.X., and Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long QT syndrome. Circulation 98 (1998) 1928-1936
48. Yan G.X., Lankipalli R.S., Burke J.F., Musco S., and Kowey P.R. Ventricular repolarization components on the electrocardiogram: Cellular basis and clinical significance. J Am Coll Cardiol 42 (2003) 401-409
49. Yan G.X., Rials S.J., Wu Y., Liu T., Xu X., Marinchak R.A., et al. Ventricular hypertrophy amplifies transmural repolarization dispersion and induces early afterdepolarization. Am J Physiol Heart Circ Physiol 281 (2001) H1968-H1975
50. Yan G.X., Shimizu W., and Antzelevitch C. Characteristics and distribution of M cells in arterially-perfused canine left ventricular wedge preparations. Circulation 98 (1998) 1921-1927
51. Yan G.X., Wu Y., Liu T., Wang J., Marinchak R.A., and Kowey P.R. Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-qt syndrome: Direct evidence from intracellular recordings in the intact left ventricular wall. Circulation 103 (2001) 2851-2856
52. Yap Y.G., and Camm A.J. Drug induced QT prolongation and torsades de pointes. Heart 89 (2003) 1363-1372